Business
Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions. Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with si
About this update from Inventiva Sa
[{"type":"image","alt":"INVENTIVA","displaySize":"","headline":null,"caption":"INVENTIVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":142,"url":"https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IFR.Gz27ItPSlaHquTiPVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/fef5472de2e52c88120abbdb39dcd123","width":300,"height":142}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions.","length":151,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":151,"olType":false},{"type":"text","content":"Daix (France), New York City (New York, United States), May 5, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that the Board of Directors called the second tranche of its previously announced1 structured financing of up to €348 million (the “Structured Financing”), for gross proceeds of €115.6 million (net proceeds of €108.5 million) (the “T2 Transaction”).","length":649,"tagName":"p"},{"type":"text","content":"Frederic Cren, Chief Executive Officer of Inventiva, stated: "We are pleased to have achieved the timely enrollment of NATiV3 and met all the conditions for the issuance of this second tranche. The quality of the investors that participated in this financing is a testimony of the strength of the clinical data generated so far with lanifibranor in patients with MASH. With enrollment of the pivotal Phase 3 completed, we are now focusing on making of lanifibranor the second oral drug for the treatment of MASH if approved. MASH is a disease for which we believe lanifibranor profile, especially in patients with advanced fibrosis and type 2 diabetes, is poised to play a key role in addressing the high unmet medical needs of patients with MASH."","length":763,"tagName":"p"},{"type":"text","content":"The Board of Directors confirm...